Mostrar el registro sencillo del ítem
dc.contributor.author | Garcia-Delgado, Regina | |
dc.contributor.author | de Miguel, Dunia | |
dc.contributor.author | Bailen, Alicia | |
dc.contributor.author | Ramon Gonzalez, Jose | |
dc.contributor.author | Bargay Lleonart, Joan | |
dc.contributor.author | Falantes, Jose F. | |
dc.contributor.author | Andreu, Rafael | |
dc.contributor.author | Fernando, Ramosh | |
dc.contributor.author | Tormo, Mar | |
dc.contributor.author | Brunet, Salut | |
dc.contributor.author | Figueredo, M. A. | |
dc.contributor.author | Casano, Javier | |
dc.contributor.author | Medina, Angeles | |
dc.contributor.author | Badiella, Llorenc | |
dc.contributor.author | Fernandez Jurado, Antonio | |
dc.contributor.author | Sanz, Guillermo | |
dc.contributor.author | Asociacion Andaluza de Hematologia | |
dc.date.accessioned | 2024-07-03T11:09:20Z | |
dc.date.available | 2024-07-03T11:09:20Z | |
dc.date.issued | 2014-07 | |
dc.identifier.citation | Garcia-Delgado R, De Miguel D, Bailen A, Ramon Gonzalez J, Bargay Lleonart J, Falantes JF, et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk Res. 2014 Jul;38(7):744-50. Epub 2014 Mar 19. | en |
dc.identifier.issn | 0145-2126 | |
dc.identifier.other | http://hdl.handle.net/20.500.13003/17327 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19996 | |
dc.description.abstract | We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules. | en |
dc.description.sponsorship | The authors received editorial/writing support provided by Christian Geest, PhD, from Excerpta Medica, funded by Celgene Corporation. The authors had full access to the data and are fully responsible for content and editorial decisions for this manuscript. | es_ES |
dc.language.iso | eng | en |
dc.publisher | Elsevier | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/ | * |
dc.subject | Acute myeloid leukemia | |
dc.subject | Azacitidine | |
dc.subject | Dosing schedules | |
dc.subject | Myelodysplastic syndromes | |
dc.subject | Overall survival | |
dc.subject | Safety | |
dc.subject.mesh | Antimetabolites, Antineoplastic | * |
dc.subject.mesh | Aged, 80 and over | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Leukemia, Myeloid, Acute | * |
dc.subject.mesh | Azacitidine | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Male | * |
dc.subject.mesh | Female | * |
dc.subject.mesh | Proportional Hazards Models | * |
dc.subject.mesh | Myelodysplastic Syndromes | * |
dc.subject.mesh | Retrospective Studies | * |
dc.title | Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia | en |
dc.type | research article | en |
dc.rights.license | Attribution-NonCommercial-NoDerivs 3.0 Unported | * |
dc.identifier.pubmedID | 24795069 | es_ES |
dc.format.volume | 38 | es_ES |
dc.format.number | 7 | es_ES |
dc.format.page | 744-750 | es_ES |
dc.identifier.doi | 10.1016/j.leukres.2014.03.004 | |
dc.relation.publisherversion | https://dx.doi.org/10.1016/j.leukres.2014.03.004 | en |
dc.identifier.journal | Leukemia Research | es_ES |
dc.rights.accessRights | open access | en |
dc.subject.decs | Modelos de Riesgos Proporcionales | * |
dc.subject.decs | Síndromes Mielodisplásicos | * |
dc.subject.decs | Femenino | * |
dc.subject.decs | Masculino | * |
dc.subject.decs | Azacitidina | * |
dc.subject.decs | Humanos | * |
dc.subject.decs | Persona de Mediana Edad | * |
dc.subject.decs | Anciano | * |
dc.subject.decs | Anciano de 80 o más Años | * |
dc.subject.decs | Antimetabolitos Antineoplásicos | * |
dc.subject.decs | Estudios Retrospectivos | * |
dc.subject.decs | Adulto | * |
dc.subject.decs | Leucemia Mieloide Aguda | * |
dc.identifier.scopus | 2-s2.0-84902116204 | |
dc.identifier.wos | 339339400005 | |
dc.identifier.pui | L53121904 |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |